Novartis (NOVN) Given a CHF 90 Price Target at Deutsche Bank

Novartis (VTX:NOVN) has been given a CHF 90 price objective by equities research analysts at Deutsche Bank in a research note issued on Monday. The firm presently has a “neutral” rating on the stock. Deutsche Bank’s price target indicates a potential upside of 7.30% from the stock’s previous close.

NOVN has been the topic of several other research reports. set a CHF 90 target price on shares of Novartis and gave the company a “buy” rating in a research report on Tuesday, September 19th. Baader Bank set a CHF 90 target price on shares of Novartis and gave the company a “buy” rating in a research report on Monday, October 30th. Berenberg Bank set a CHF 88 target price on shares of Novartis and gave the company a “neutral” rating in a research report on Monday, October 30th. Sanford C. Bernstein set a CHF 97 target price on shares of Novartis and gave the company a “buy” rating in a research report on Thursday, October 26th. Finally, Societe Generale set a CHF 95 target price on shares of Novartis and gave the company a “buy” rating in a research report on Wednesday, October 25th. Three analysts have rated the stock with a sell rating, six have given a hold rating and seven have issued a buy rating to the stock. Novartis has an average rating of “Hold” and a consensus price target of CHF 87.38.

Shares of Novartis (VTX NOVN) opened at CHF 83.88 on Monday. The company has a market cap of $217,770.00 and a price-to-earnings ratio of 30.84. Novartis has a 52-week low of CHF 69.50 and a 52-week high of CHF 85.40.

COPYRIGHT VIOLATION NOTICE: This report was originally reported by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this report on another publication, it was illegally stolen and republished in violation of international copyright & trademark law. The correct version of this report can be viewed at https://stocknewstimes.com/2018/01/15/novartis-novn-given-a-chf-90-price-target-at-deutsche-bank.html.

About Novartis

Novan, Inc, a clinical-stage drug development company, focuses on the development and commercialization of nitric oxide-based therapies in dermatology. Its lead product candidate is SB204, a cosmetically elegant topical gel that targets multiple mechanisms of action for the treatment of acne vulgaris.

Analyst Recommendations for Novartis (VTX:NOVN)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply